ANR.AU Anatara Lifesciences Ltd

Healthcare Biotechnology Australian Securities Exchange
0.0080 AUD
Close of Oct 28, 2026
0.0080 0.0170
Market cap
AUD 2.53M
P/E
-
P/B
3.56x
ROE
-131.2%
Dividend yield
-
Fundamental score
1.1/5

Ratios use the latest price and the fiscal year ending Jun 2026.

Is ANR.AU undervalued?

Graham number

The Graham number of Anatara Lifesciences Ltd cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Anatara Lifesciences Ltd fundamental analysis

6 of 21 checks passed

ROE 0/2

Low return on equity (-131.2%), below 10%.

ROA 0/1

Return on assets (-113.8%) is below the industry median (-51.4%).

Profit Consistency 0/2

Not profitable for at least 3 consecutive years.

Earnings Growth 5Y 1/1

Earnings per share grew over the past 5 years.

Earnings Acceleration 0/1

Not enough positive earnings history to compare last year's growth with the 5-year average.

Earnings Growth vs Industry 1/1

Last year's EPS growth (64.8%) is above the industry median (-5.3%).

Revenue Growth 0/2

Revenue did not grow over the past 3 years or is not reported.

Short-term Liquidity 1/1

Current assets cover short-term liabilities.

Long-term Liabilities 1/1

Current assets cover long-term liabilities.

Debt to Equity 0/2

Debt to equity cannot be calculated: debt is not reported or equity is negative.

Debt Trend 0/1

Debt to equity has risen over the past 5 years.

Cash Runway 1/2

Cash covers 1.4 years of the current cash burn.

PE vs Market 0/1

PE is negative or not available.

PE vs Industry 0/1

PE is negative or not available.

PBV 1/1

Price to book (3.6x) is below the industry median (4.4x).

Graham Number 0/1

Graham number needs positive earnings and book value.

PEG 0/1

PEG needs positive PE and positive 5-year earnings growth.

Dividend Yield 0/2

No dividend paid in the last reported year.

Dividend Stability 0/2

Dividends were not paid steadily for the past 5 years.

Dividend Growth 0/1

Dividends paid did not grow over the past 5 years.

Payout Ratio 0/1

No dividend, or no profit to pay it from.

Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score

Anatara Lifesciences Ltd stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Anatara Lifesciences Ltd

Anatara Lifesciences Ltd engages in the research, development, and commercialization of evidence-based solutions for gastrointestinal diseases in Australia. The company's products include irritable bowel syndrome; and Detach for the treatment of diarrhea in piglets. It also develops anti-obesity project, an oral complementary medication to assist weight reduction and control. Anatara Lifesciences Ltd was incorporated in 2010 and is based in Adelaide, Australia.

Full company profile